๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis

โœ Scribed by Mario Cruciani; Carlo Mengoli; Marina Malena; Oliviero Bosco; Giovanni Serpelloni; Paolo Grossi


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
148 KB
Volume
12
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

โœฆ Synopsis


We performed a meta-analysis to determine whether antifungal prophylaxis decreases infectious morbidity and mortality in liver transplant patients. We searched for randomized trials dealing with prophylaxis with systemic antifungal agents. We used a fixed effect model, with risk ratio (RR) and 95% confidence interval (CI); we assessed study quality for heterogeneity and publication bias. Six studies (5 double-blind), for a total of 698 patients, compared fluconazole, itraconazole, or liposomal amphotericin to placebo (5 studies) or oral nystatin. Prophylaxis reduced colonization (RR, 0.45; CI, 0.37-0.55), total proven fungal infections (RR, 0.31; CI, 0.21-0.46), which included both superficial (RR, 0.27; CI, 0.16-0.45) and invasive (RR, 0.33; CI, 0.18-0.59) infections, and mortality attributable to fungal infection (RR, 0.30; CI, 0.12-0.75). Prophylaxis did not affect overall mortality (RR, 1.06; CI, 0.69-1.64) or empiric treatment for suspected fungal infection (RR, 0.80; CI, 0.39-1.67). The beneficial effect of antifungal prophylaxis was predominantly associated with the reduction of Candida albicans infection and mortality attributable to C. albicans. Compared to controls, however, patients receiving prophylaxis experienced a higher proportion of episodes of non-albicans Candida, and in particular of C. glabrata. No beneficial effect on invasive Aspergillus infection was observed. In conclusion, our analysis shows a clear, though limited, beneficial effect of antifungal prophylaxis in liver transplant patients. Concerns about the selection of triazole-resistant Candida strains, however, are realistic, and the potential disadvantages of prophylaxis should be weighed against the established benefits.


๐Ÿ“œ SIMILAR VOLUMES


Antifungal prophylaxis in liver transpla
โœ Gregory A. Eschenauer; Simon W. Lam; Peggy L. Carver ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 169 KB

Although the overall incidence of fungal infections in liver transplant recipients has declined, these infections still contribute significantly to the morbidity and mortality of patients with risk factors for infection. Although antifungal prophylaxis has been widely studied and practiced, no conse

Tuberculosis in liver transplant recipie
โœ Jon-Erik C. Holty; Michael K. Gould; Laura Meinke; Emmet B. Keeffe; Stephen J. R ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 249 KB ๐Ÿ‘ 1 views

Mycobacterium tuberculosis (MTB) causes substantial morbidity and mortality in liver transplant recipients. We examined the efficacy of isoniazid latent Mycobacterium tuberculosis infection (LTBI) treatment in liver transplant recipients and reviewed systematically all cases of active MTB infection

Erratum: Antifungal prophylaxis in liver
โœ Gregory A. Eschenauer; Simon W. Lam; Peggy L. Carver ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 120 KB

UNOS status 4 (life support in ICU) 146 6.3 (2.4-16.7) George 1997 ( 14 ) Donor CMV รพ/recipient -146 4.8 (2.0-11.8) George 1997 ( 14 ) UNOS class I (life support in ICU) 172 3.5 (1.7-7.0) Winston 1999 ( 23 ) Fungal colonization at baseline 172 2.3 (1.2-4.3) Winston 1999 ( 23 ) Pretransplant SCr 3 mg

Use of sirolimus in liver transplant rec
โœ Sumeet K. Asrani; Michael D. Leise; Colin P. West; M. Hassan Murad; Rachel A. Pe ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 419 KB ๐Ÿ‘ 1 views

Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and especially in those with calcineurin inhibitor (CNI)-associated nephrotoxicity. We conducted a systematic review of all randomized controlled trials and observational studies to test the hypothesis that the u

The role of selective digestive decontam
โœ Nasia Safdar; Adnan Said; Michael R. Lucey ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 200 KB ๐Ÿ‘ 1 views

Selective digestive decontamination (SDD) refers to the use of antimicrobials to reduce the burden of aerobic gram-negative bacteria and/or yeast in the intestinal tract to prevent infections caused by these organisms. Liver transplant patients are highly vulnerable to bacterial infection particular

Liver transplantation for hepatocellular
โœ Houben, Karin W. ;McCall, John L. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 53 KB

Liver resection is the treatment of choice for hepatocellular carcinoma (HCC) occurring in the absence of underlying chronic liver disease. Orthotopic liver transplantation (OLT) is reserved for patients with unresectable disease but remains controversial. The aim of this study was to review the pub